Liver Enzymes: Potential Cardiovascular Risk Markers?

Author(s): Eirini Lioudaki, Emmanuel S. Ganotakis, Dimitri P. Mikhailidis

Journal Name: Current Pharmaceutical Design

Volume 17 , Issue 33 , 2011

Become EABM
Become Reviewer


Several cross-sectional studies have reported a relationship between elevated serum activity of liver enzymes [e.g. alanine aminotransferase (ALT) and gamma-glutamyltransferase (γGT)] and metabolic syndrome (MetS) and/or diabetes mellitus (DM). Raised serum activity of liver enzymes independently predicted the future development of MetS and DM as well as cardiovascular (CV) events and/or total/CV mortality in prospective studies. However, this association was not consistently demonstrated and it appears to be independent of alcohol intake. Even though these associations can be partly attributed to non-alcoholic fatty liver disease (NAFLD) and insulin resistance, there may be additional underlying mechanisms that contribute to the increased CV risk (e.g. inflammation and oxidative stress). The association of γGT with atherosclerotic plaque is of particular importance. The present review considers the link between serum liver enzyme activities and vascular risk. The links with DM and MetS are also discussed.

Keywords: Liver enzyme, alanine aminotransferase, gamma-glutamyltransferase, aspartate aminotransferase, non-alcoholic fatty liver disease, cardiovascular disease, cardiovascular risk, metabolic syndrome, diabetes mellitus, atherosclerotic plaque

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2011
Page: [3632 - 3643]
Pages: 12
DOI: 10.2174/138161211798220945
Price: $65

Article Metrics

PDF: 16